108 completed, 70 recruiting, 51 unknown, 44 terminated. 343 Phase 2, 58 Phase 1, 17 Phase 3.
Follow Cholangiocarcinoma: new trials by email Literature Review of Cholangiocarcinoma trials Research Report on Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma Tislelizumab - Cholangiocarcinoma, Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | National Cheng-Kung University Hospital | 35 | 2027-06-01 | 2026-11-17 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma 3D185 - Cholangiocarcinoma,Adult | Phase 2 | Not yet recruiting | 3D Medicines (Beijing) Co., Ltd. | 50 | 2026-12-01 | 2026-09-09 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-12-01 | 2026-11-16 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma Histotripsy, Durvalumab, Biopsy - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | University of Wisconsin, Madison | 12 | 2026-11-01 | 2026-10-30 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging - Cholangiocarcinoma | Phase 2 | Recruiting | University of Washington | 22 | 2026-10-08 | 2026-10-20 |
| Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma Anlotinib, TQB2868 Injection, cryoablation - Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 56 | 2026-10-01 | 2026-09-29 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin - Intrahepatic Cholangiocarcinoma (Icc) | Phase 1 / Phase 2 | Not yet recruiting | Shanghai 6th People's Hospital | 112 | 2026-09-15 | 2026-08-28 |
| A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma VG2025 - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Virogin Biotech Ltd. | 30 | 2026-08-25 | 2026-09-22 |
| Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor - Bile Duct Carcinoma, Cholangiocarcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 240 | 2026-08-10 | 2026-07-28 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2026-06-16 | 2026-06-24 |
| HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Lianghe Lu | 35 | 2026-06-11 | 2026-09-25 |
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. GV20-0251, anti-PD-1 monoclonal antibodies - Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | GV20 Therapeutics | 227 | 2026-06-02 | 2026-06-08 |
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Yale University | 54 | 2026-06-02 | 2026-09-08 |
| Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations Becotatug Vedotin, Pucotenlimab, Gemcitabine - Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 164 | 2026-05-20 | 2026-05-20 |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors ASP546C - Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 150 | 2026-05-04 | 2026-11-13 |
Showing 20 of 343. Sign in to see all of them.
Gallbladder Neoplasms (61) · Biliary Tract Neoplasms (56) · Bile Duct Neoplasms (36) · Colorectal Neoplasms (27) · Carcinoma, Hepatocellular (26) · Pancreatic Neoplasms (25) · Stomach Neoplasms (22) · Cirrhosis, Familial, with Pulmonary Hypertension (19) · Liver Neoplasms (19) · Klatskin Tumor (18) · Breast Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (17) · Neoplasm Metastasis (17) · Ovarian Neoplasms (16)
Neoplasms by Histologic Type (343) · Neoplasms, Glandular and Epithelial (343) · Adenocarcinoma (341) · Carcinoma (335) · Neoplasms (329) · Neoplasms by Site (162) · Digestive System Diseases (155) · Digestive System Neoplasms (153) · Biliary Tract Diseases (110) · Gallbladder Diseases (61) · Biliary Tract Neoplasms (54) · Gastrointestinal Diseases (47) · Endocrine Gland Neoplasms (41) · Endocrine System Diseases (41) · Gastrointestinal Neoplasms (41)
Gemcitabine (77) · Cisplatin (47) · Oxaliplatin (32) · durvalumab (24) · Capecitabine (23) · Fluorouracil (22) · pembrolizumab (22) · lenvatinib (21) · Leucovorin (15) · Magnetic Resonance Spectroscopy (11) · Specimen Handling (11) · tislelizumab (11) · 130-nm albumin-bound paclitaxel (9) · Biopsy (9) · Drug Therapy (9)
National Cancer Institute (NCI) (19) · Shanghai Zhongshan Hospital (11) · Fudan University (10) · Tianjin Medical University Cancer Institute and Hospital (9) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (7) · Peking Union Medical College Hospital (5) · Sun Yat-sen University (5) · The First Affiliated Hospital with Nanjing Medical University (5) · Memorial Sloan Kettering Cancer Center (4) · University of Zurich (4) · AIO-Studien-gGmbH (3) · Asan Medical Center (3) · Hoffmann-La Roche (3) · Incyte Corporation (3) · M.D. Anderson Cancer Center (3)
United States (133) · China (109) · South Korea (33) · France (28) · Germany (28) · Italy (24) · Spain (23) · Taiwan (19) · Australia (17) · Canada (17) · Netherlands (17) · United Kingdom (17) · Belgium (15) · Japan (11) · Denmark (8)
Peng Wang, MD (4) · Jonathan M Hernandez, M.D. (3) · Tim F Greten, M.D. (3) · Benjamin Tan, M.D. (2) · Feng Cheng, MD (2) · Hai-Tao Zhao, M.D. (2) · Jia Fan, MD & PhD (2) · Jian Zhou, MD & PhD (2) · Jian Zhou, MD&PhD (2) · Jordi Bruix, MD (2) · Nilofer S Azad (2) · Patricia M LoRusso (2)
PMID 40812353, PMID 20375404, PMID 29433850, PMID 30998813, PMID 24146220, PMID 27095655, PMID 28818953, PMID 30420614, PMID 32461347, PMID 33198671, PMID 15192785, PMID 15319238, PMID 17543307, PMID 18751418, PMID 18981929, PMID 19097774, PMID 19491285, PMID 19626372, PMID 20014463, PMID 20165987, PMID 20662793, PMID 20678012, PMID 22261548, PMID 22367707, PMID 22537432, PMID 22762399, PMID 23043667, PMID 23480759, PMID 23846786, PMID 24461131, PMID 24581682, PMID 24681130, PMID 24769639, PMID 24852116, PMID 25095718, PMID 25111859, PMID 25538178, PMID 25632066, PMID 25738477, PMID 25763789, PMID 25899049, PMID 25937868, PMID 26179201, PMID 26487951, PMID 26540314, PMID 26598942, PMID 26695839, PMID 27114433, PMID 27234522, PMID 27627808
2023 (7), 2015 (4), 2016 (4), 2025 (4), 2019 (2), P30CA138292 (2), U10CA032102 (2), U10CA180820 (2), U10CA180888 (2), UM1CA186689 (2), UM1CA186691 (2), 2009 (1), 2014 (1), 2017 (1), 2018 (1)